Clinical trials: Cognition
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Alzheimer Disease, Mild Cognitive Impairment
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States.
- Trial name
- GERAS-US (NCT02951598)
- Testing
- Florbetapir F 18 PET Scan
- Where
- 77 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Schizophrenia, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical…
- Conditions
- Schizophrenia, Central Nervous System Diseases, Cognition
- Trial name
- NCT00968851
- Testing
- EVP-6124
- Where
- 31 sites in United States, Russia and 2 more
- Volunteers
- 317 people
- Sponsor
- FORUM Pharmaceuticals Inc
Menopause, Hot Flashes
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
This is a proof-of-concept phase 2 clinical trial to investigate the effect of the phytoestrogenic supplement PhytoSERM on vasomotor symptoms and other symptoms associated with the menopausal transition, and on blood-based…
- Trial name
- HF-Relief (NCT06186531)
- Testing
- PhytoSERM
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- NeuTherapeutics
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
- Trial name
- NCT05463731
- Testing
- Remternetug (IV), Remternetug (SC)
- Where
- 76 sites in United States, Japan
- Volunteers
- 1,667 people
- Sponsor
- Eli Lilly and Company
Huntington's Disease
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months).
- Trial name
- NCT00387270
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medivation, Inc.
Mild Cognitive Impairment, Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or…
- Trial name
- NCT01661673
- Testing
- EVP-0962
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- FORUM Pharmaceuticals Inc
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cognition Disorders
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer…
- Trial name
- A4 (NCT02008357)
- Testing
- Solanezumab
- Where
- 68 sites in United States, Australia and 2 more
- Volunteers
- 1,169 people
- Sponsor
- Eli Lilly and Company
Cognitive Impairment Associated With Schizophrenia (CIAS)
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days.
- Trial name
- NCT07191483
- Testing
- KYN-5356 low dose, KYN-5356 Medium Dose, KYN-5356 High Dose
- Where
- 15 sites in United States
- Volunteers
- 149 people
- Sponsor
- Kynexis B.V.
Psychotic Disorders
Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder
This is a 24-week, observational, prospective study to evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan.
- Trial name
- NCT00541502
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Cognitive Dysfunction, Cognitive Impairment
CAMCI: Advancing the Use of Computerized Screening in Healthcare
Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to…
- Conditions
- Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
- Trial name
- NCT03512301
- Testing
- CAMCI, MoCA, Clinical Adjudication
- Where
- 4 sites in United States
- Volunteers
- 773 people, healthy volunteers welcome
- Sponsor
- Psychology Software Tools, Inc.
Age-related Cognitive Decline
Attention Training for Learning Enhancement and Resilience Trial
Healthy aging is associated with a decline in multiple cognitive domains, as well as motor control function. The long-term consequences of cognitive and functional impairment resulting from age-related cognitive decline are well…
- Trial name
- ALERT (NCT02416401)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- Posit Science Corporation
Cognitive Disorders
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of…
- Trial name
- TAYPES (NCT02321475)
- Testing
- EGb761®
- Where
- 2 sites in Russia
- Volunteers
- 54 people
- Sponsor
- Ipsen
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
- Trial name
- NCT06585449
- Testing
- ALN-HTT02
- Where
- 19 sites in Canada, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Alnylam Pharmaceuticals